Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Greenbrook Tms Inc GBNHF

Greenbrook TMS Inc. is a provider of Transcranial Magnetic Stimulation (TMS) therapy and Spravato (esketamine nasal spray) therapy in the United States for the treatment of depressive disorder (MDD) and other mental health disorders. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. The Company operates a network of outpatient mental health service centers that specialize in Treatment across the United States. It offers Treatment Centers in convenient locations to provide easy access to patients and clinicians. The Company owns and operates 133 Treatment Centers in the Commonwealths of Massachusetts, Virginia and Pennsylvania and the States of Maryland, North Carolina, Missouri, Illinois, Ohio, Texas, Connecticut, Florida, and South Carolina.


OTCQB:GBNHF - Post by User

Bullboard Posts
Next >>
Post by retiredcfon Mar 11, 2020 10:00am
355 Views
Post# 30792709

Record Results

Record ResultsAnd unfortunate timing. GLTA

Greenbrook TMS Reports Record Fourth Quarter and Year End 2019 Financial Results

Greenbrook TMS Inc. (TSX: GTMS) (“Greenbrook” or the “Company”) today announced its fourth quarter (“Q4 2019”) and year-end 2019 (“Fiscal 2019) operational and financial results. All values in this press release are in United States dollars, unless otherwise stated. 

FOURTH QUARTER AND YEAR END 2019 FINANCIAL AND OPERATIONAL HIGHLIGHTS

  • Q4 2019 revenue increased by 77% to a record $12.5 million, up $5.4 million from the fourth quarter of fiscal 2018 (“Q4 2018”). 
  • Fiscal 2019 revenue increased by 68% to $35.7 million, up $14.4 million from the 2018 fiscal year-end (“Fiscal 2018”). 
  • Q4 2019 regional operating income increased by 36% to $1.9 million, up $0.5 million from Q4 2018(1)
  • Fiscal 2019 regional operating income increased by 54% to $4.3 million, up $1.5 million from Fiscal 2018(1)
  • Added 62 TMS Centers during Fiscal 2019, 55 of which are active TMS Centers, bringing our total to 121 TMS Centers as at the date of this press release. 
  • Completed the acquisition of Achieve TMS Centers, LLC and Achieve TMS Alaska, LLC (collectively, “Achieve TMS”), which, provides the Company with a national footprint of over 100 TMS Centers. The acquisition also provides a platform for further expansion in the western United States, which is enhanced by Achieve TMS’ excellent brand recognition, physician reputation and high visibility in the local TMS community.

Bullboard Posts
Next >>